Revium Recovery, Inc. (RVRC)
1.43
0.00 (0.00%)
USD |
OTCM |
Aug 24, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 86.84M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 175.0% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 98.64% |
Profile
| Revium Recovery, Inc. is a biotechnology company focused on the development of highly effective lipid-based therapies that redefine treatment standards. Its pipeline features a next-generation liposomal antibiotic targeting resistant bacterial infections, alongside a potent liposomal cancer adjuvant, engineered to deliver superior efficacy, improved safety, and precise targeting. Its Therapeutic Areas include Antimicrobial Resistance, Solid Tumors & Immunization. The company was founded on January 24, 1997 and is headquartered in Herzliya, Israel. |
| URL | http://www.reviumrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Revium Recovery, Inc. is a biotechnology company focused on the development of highly effective lipid-based therapies that redefine treatment standards. Its pipeline features a next-generation liposomal antibiotic targeting resistant bacterial infections, alongside a potent liposomal cancer adjuvant, engineered to deliver superior efficacy, improved safety, and precise targeting. Its Therapeutic Areas include Antimicrobial Resistance, Solid Tumors & Immunization. The company was founded on January 24, 1997 and is headquartered in Herzliya, Israel. |
| URL | http://www.reviumrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |